Interventions for preventing oral candidiasis for patients with cancer receiving treatment
Interventions for preventing oral candidiasis for patients with cancer receiving treatment
Cochrane Review
23 SoF Entries
Summary of Findings
Key results and quality assessments using GRADE methodology
| Outcome | Effect | Participants | Studies | Certainty |
|---|---|---|---|---|
|
Symptom relief: short-term (3 months) - Mean VAS pain score
Placebo |
1.26 | - | - | Not assessed |
|
Change in quality of life (QoL): short-term (3 months) - Mean Beck Depression Inventory score
Placebo |
nan | - | - | Not assessed |
|
Change in taste
Placebo |
nan | - | - | Not assessed |
|
Change in feeling of dryness
Placebo |
nan | - | - | Not assessed |
|
Adverse effects - Dizziness
Placebo |
11.61 | - | - | Not assessed |
|
Adverse effects - Drowsiness
Placebo |
4.75 | - | - | Not assessed |
|
Symptom relief: short-term (≤ 3 months) - Bespoke geographical burning distribution numerical scale (0-4) (Dichotomised)
Placebo |
4.0 | - | - | Not assessed |
|
Change in quality of life (QoL)
Placebo |
nan | - | - | Not assessed |
|
Adverse effects - Drowsiness (gabapentin alone)
Placebo |
31.95 | - | - | Not assessed |
|
Change in quality of life (QoL): short-term (3 months) - Mean depression score
Placebo |
-0.2 | - | - | Not assessed |
|
Change in taste: short-term (≤ 3 months) - Mean taste test score
Placebo |
-1.0 | - | - | Not assessed |
|
Adverse effects
Placebo |
nan | - | - | Not assessed |
|
Symptom relief: short-term (3 months) - Bespoke BMS symptomology change scale (Dichotomised)
Placebo |
5.0 | - | - | Not assessed |
|
Symptom relief: short-term (3 months)
Placebo |
nan | - | - | Not assessed |
|
Change in quality of life (QoL): short-term (3 months) - Mean OHIP-14 score
Placebo |
0.93 | - | - | Not assessed |
|
Change in QoL - anxiety: short-term (3 months) - Mean HAD anxiety score
Placebo |
-2.85 | - | - | Not assessed |
|
Change in QoL - depression: short-term (3 months) - Mean HAD depression score
Placebo |
-1.87 | - | - | Not assessed |
|
Symptom relief: short-term (3 months) - Mean VAS score
Placebo |
-30.36 | - | - | Not assessed |
|
Change in quality of life (QoL): short-term (3 months) - Mean OHIP-49 score
Placebo |
-9.2 | - | - | Not assessed |
|
Symptom relief: long-term (> 3 to 6 months) - Mean VAS pain score
Placebo |
-3.2 | - | - | Not assessed |
|
long term symptom relief (> 3 to 6 months)
Placebo |
-2.6 | - | - | Not assessed |
|
Change in taste: short-term (3 months) - Mean Quantitative Sensory Testing (QST) score: gustative threshold
Placebo |
nan | - | - | Not assessed |
|
Change in feeling of dryness: short-term (3 months) - Xerostomia questionnaire
Placebo |
nan | - | - | Not assessed |
GRADE Certainty of Evidence:
High
Very confident in the effect estimate
Moderate
Moderately confident in the effect estimate
Low
Limited confidence in the effect estimate
Very Low
Very little confidence in the effect estimate
Review Information
| Review ID: | CD002779 |
| Outcomes: | 23 assessed |
Related Content
Evidence Quality Distribution:
Not assessed:
23